Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor …
A Sacré, P Barthélémy, C Korenbaum, M Burgy… - Acta …, 2016 - Taylor & Francis
Background: About 40% of metastatic clear-cell renal cell carcinoma (m-ccRCC) patients
receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor …
receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor …
[PDF][PDF] Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor …
A Sacré, P Barthélémy, C Korenbaum, M Burgy… - researchgate.net
Background: About 40% of metastatic clear-cell renal cell carcinoma (m-ccRCC) patients
receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor …
receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor …
Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor …
A Sacré, P Barthélémy, C Korenbaum, M Burgy… - Acta …, 2016 - actaorthop.org
Background: About 40% of metastatic clear-cell renal cell carcinoma (m-ccRCC) patients
receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor …
receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor …
Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor …
A Sacré, P Barthélémy… - Acta oncologica …, 2016 - pubmed.ncbi.nlm.nih.gov
Background About 40% of metastatic clear-cell renal cell carcinoma (m-ccRCC) patients
receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor …
receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor …
[PDF][PDF] Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor …
A Sacré, P Barthélémy, C Korenbaum… - ACTA …, 2016 - scholar.archive.org
Background: About 40% of metastatic clear-cell renal cell carcinoma (m-ccRCC) patients
receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor …
receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor …
Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor …
A Sacré, P Barthélémy, C Korenbaum… - Acta …, 2016 - search.ebscohost.com
Background: About 40% of metastatic clear-cell renal cell carcinoma (m-ccRCC) patients
receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor …
receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor …
Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor …
A Sacré, P Barthélémy, C Korenbaum… - Acta Oncologica …, 2015 - europepmc.org
About 40% of metastatic clear-cell renal cell carcinoma (m-ccRCC) patients receive a
second-line targeted therapy after failure of anti-vascular endothelial growth factor receptor …
second-line targeted therapy after failure of anti-vascular endothelial growth factor receptor …
[PDF][PDF] Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor …
A Sacré, P Barthélémy, C Korenbaum, M Burgy… - ACTA …, 2016 - academia.edu
Background: About 40% of metastatic clear-cell renal cell carcinoma (m-ccRCC) patients
receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor …
receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor …